Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonoprazan versus esomeprazole in symptomatic gastro-esophageal reflux disease with partial response to high-dose proton pump inhibitor therapy
2015-001154-14Phase 2Completed
- Sponsor
- Takeda
- Start
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vonoprazan and esomeprazole in gastroesophageal reflux disease (GERD) (3 arms), sponsored by Takeda. Primary endpoint: Percentage of heartburn-free 24-hour periods. Started Mar 2016; status: completed.
02
Drugs
vonoprazanesomeprazole
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on 2015-001154-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001154-14.